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In obesity and in most situations of 
 insulin-resistance, β-cells compensate for 
this hormonal resistance for long periods 
of time by an increase in secretory capac-
ity and in β-cell mass. In animal models of 
insulin-resistance there is islet hyperplasia 
(1–3) and very recently a clear correlation 
between BMI and β-cells mass was shown 
in humans (4). The driving forces that can 
contribute to the increased β-cell mass in 
insulin-resistant states are not completely 
understood. It is well-established that glu-
cose itself is able to induce β-cell hyperpla-
sia (3, 5). However in many situations of 
insulin-resistance the hyperplastic response 
comes prior to any change in circulating 
glucose levels, indicating that other factors 
independent of glucose may contribute to 
the islet hyperplasia. Among circulating hor-
mones and/or growth factors such as growth 
hormone (GH), insulin-like growth factor 
I (IGF-I), prolactin, and placental lactogen 
were implicated in islet hyperplasia associ-
ated with insulin-resistance. However, some 
data does not support the contribution of 
these hormones in islet hyperplasia. For 
example, GH and IGF-I were not altered in 
diet-induced obesity (DIO) mice and most 
insulin-resistant animal models investigated 
were male, making prolactin and the placen-
tal lactogen improbable candidates. In the 
past 4 years a novel pathway involving a neu-
ral relay and two hormones – betatrophin 
and hepatocyte growth factor (HGF) – were 
implicated as an inter-organ communica-
tion system associated to the compensatory 
response of β cells in face of insulin-resist-
ance (6–8). In this commentary we will focus 
on evidence showing the role of this novel 
pathway in islet hypertrophy associated with 
obesity and insulin-resistance.
In a recent publication by Yi and col-
laborators (8), the authors identified beta-
trophin, a novel hormone that increases 
in insulin-resistant states and controls 
 pancreatic β cell proliferation. This hor-
mone was recognized through the infusion 
in mice of the insulin receptor antagonist 
(S961) able to induce insulin-resistance, and 
also provoke at a dose-dependent manner 
a dramatic pancreatic β cell proliferation. 
By microarray, they identified the hormone 
betatrophin from the liver and adipose tis-
sue of these animals, which showed that it 
is able to induce beta cell proliferation. In 
addition, the authors also demonstrated 
that the betatrophin mRNA was increased 
in the liver from ob/ob and db/db mice 
(three to four-fold), as well as during the 
mice pregnancy (∼20-fold). As discussed 
below, HGF is a growth factor that plays a 
key role in regulation of islet mass increases 
along with hyperinsulinemia in animal 
models of insulin-resistance, therefore 
could also play a role, however, this pos-
sibility was not addressed by Yi et al. (8). 
Additional aspects of the work deserve fur-
ther clarification, although Yi et al. showed 
a possible cause-effect relationship between 
betatrophin and an increase in pancreatic 
β cell proliferation in their approach, some 
aspects were not thoroughly clarified. For 
example, they did not demonstrate the 
correlation between circulating levels of 
betatrophin and the increase in islet mass; 
most of the experiments are in an artifi-
cial model of insulin-resistance, based on 
the use of an insulin receptor antagonist, 
and not in the traditional models of obe-
sity and or insulin-resistance, mainly based 
on a diet-induced obesity (9, 10); and, the 
increase in mRNA of betatrophin is much 
higher in pregnancy than in ob/ob and db/db 
mice, but the increase in islet mass is usually 
higher in these genetic models compared to 
pregnancy (1, 11). In addition, the regula-
tions of complex processes that are evolu-
tionary conserved and/or adaptive traits, 
such as insulin-resistance is usually involve 
redundant mechanisms. In this regard, an 
important point we would like to emphasize 
is that the compensatory increase in islet 
cell mass and hyperinsulinemia is multifac-
torial and involves central nervous system 
(CNS) (7), and at least one more growth 
factor besides betatrophin, this one known 
as HGF, as we previously demonstrated (6).
Imai and coworkers identified a neuronal 
relay, originating in the liver, which enhances 
both insulin secretion and pancreatic β-cell 
proliferation (7). They showed that block-
ing this neural relay in rodent obesity mod-
els led to an inhibition in pancreatic islet 
expansion during obesity development, 
presenting this inter-organ communica-
tion system to be physiologically involved 
in compensatory β-cell proliferation. This 
neuronal relay is connected with signaling 
pathways in the liver, since it is triggered 
by an increase in the phosphorylation of 
hepatic extracellular signal-regulated kinase 
(ERK), which is known to be activated in the 
liver of a murine obesity model (12). Thus, 
through an adenoviral gene transduction 
approach that promoted a liver-selective 
expression of a constitutively active mutant 
of mitogen-activated protein kinase/ERK 
kinase (MEK-1), they were able to induce 
insulin hypersecretion and β-cell prolifera-
tion. Moreover, they also demonstrated that 
these pancreatic effects of hepatic ERK acti-
vation were inhibited by splanchnic affer-
ent blockade, pancreatic vagus dissection, 
or midbrain transection (7).
Kahn’s group has consistently showed 
that circulating growth factors, probably 
produced by the liver, are also important in 
the connection between insulin-resistance 
and the increase in islet mass (1, 2). Also, 
our group recently published a study (6) 
that presented the HGF as one of the sys-
temic liver-derived growth factors that plays 
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β-cell mass in a dose-dependent manner; 
(3) blocking HGF shuts down the compen-
satory mechanisms; and (4) an increase in 
HGF levels seems to precede the compen-
satory response associated with insulin-
resistance, indicating that these events occur 
in a causal fashion. Additionally, blockages 
of HGF receptor (Met) worsen the already 
impaired insulin-induced insulin signaling 
in the liver of diet-induced obesity rats.
In conclusion, it is important to empha-
size that the recently described betatrophin 
is a hormone that has an important role in 
the connection between insulin-resistance 
and increased β-cell mass, but other growth 
factors such as HGF and also neural circuits 
certainly play an important role in this pro-
cess (Figure 1). The contribution of each of 
these factors in different situations of insulin-
resistance, such as in pregnancy, obesity, and 
type 2 diabetes, deserves further investigation.
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axis in the adaptive β cell growth response. 
The concept of the study, initially, was that 
since it is well-established that the HGF is a 
mesenchymal-derived pleiotropic cytokine 
that regulates cell proliferation, anti-apo-
ptosis, motility, and morphogenesis, sug-
gests that HGF may be a good candidate 
of circulating insulin-resistance-related 
β-cell growth factor. Moreover, HGF has 
at least four characteristics that suggest a 
pathophysiological link between insulin-
resistance and islet hyperplasia/hyperinsu-
linemia: (1) HGF is mainly produced by the 
liver; (2) it is under the regulation of the 
ERK pathway; (3) HGF stimulates insulin 
secretion and increased islet mass both in 
vitro and in vivo; and (4) circulating levels 
are elevated in obesity associated-insulin-
resistance. Based on this circumstantial 
evidence, we studied the role of HGF in 
insulin-resistance compensatory mecha-
nisms. Our approach aimed to show a possi-
ble causal relationship between an increase 
in circulating HGF levels and compensatory 
islet hyperplasia/hiperinsulinemia. In this 
sense, we investigated the association in a 
dose-dependent, longitudinal approach. 
Our findings showed the following: (1) 
there is a strong and consistent correlation 
between HGF and the compensatory mech-
anism from β-cells in three animal models 
of insulin-resistance; (2) that HGF increases 
FiGure 1 | Schematic representation of the effects of betatrophin and HGF hormones, as well as, 
neural circuits on islets in which these components together induce the compensatory response to 
insulin-resistance.
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